Reducing the glycolytic activity in the cells by limiting glucose availability significantly ameliorates the toxic effects of palmitate supplementation in HER2/neu-positive SKBR3 breast cancer cells (Supplementary Figure 4). The gene discussed is ERBB2; the disease is breast carcinoma.